Literature DB >> 18525127

CSF Abeta42, tau and phosphorylated tau correlate with medial temporal lobe atrophy.

Sanna-Kaisa Herukka1, Corina Pennanen, Hilkka Soininen, Tuula Pirttilä.   

Abstract

Cerebrospinal fluid (CSF) biomarkers and medial temporal lobe (MTL) atrophy predict the progression of mild cognitive impairment (MCI) to Alzheimer's disease (AD). We investigated the association between the CSF biomarkers and MTL atrophy and the ability of these measures to predict AD in MCI patients in the same study population. The study included 21 MCI patients of whom eight progressed to AD during the study. CSF biomarkers were measured by using ELISA method and volumes of MTL structures were assessed by magnetic resonance imaging (MRI). Abeta42 levels were lower and tau and phospho-tau levels were higher in progressive subjects. The progressive subjects had lower volumes in all MRI measures. Tau and phospho-tau correlated inversely with hippocampal volumes and left entorhinal cortex volume in the whole study group. In the stable group, tau correlated with hippocampal volumes. Phospho-tau [corrected] had a negative correlation whereas Abeta42 [corrected] exhibited a positive correlation with left hippocampal volume in the progressive group. These results indicate that both measures may reflect the ongoing neurodegenerative process in the progressive MCI patients. However, the order of the changes in the CSF biomarkers and MTL atrophy remain unclear due to a small number of studied subjects and study design.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18525127     DOI: 10.3233/jad-2008-14105

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  23 in total

Review 1.  Alliance for aging research AD biomarkers work group: structural MRI.

Authors:  Clifford R Jack
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

2.  MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations.

Authors:  P Vemuri; H J Wiste; S D Weigand; L M Shaw; J Q Trojanowski; M W Weiner; D S Knopman; R C Petersen; C R Jack
Journal:  Neurology       Date:  2009-07-28       Impact factor: 9.910

3.  Impact of apolipoprotein E4-cerebrospinal fluid β-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment.

Authors:  Gloria C Chiang; Philip S Insel; Duygu Tosun; Norbert Schuff; Diana Truran-Sacrey; Sky T Raptentsetsang; Paul M Thompson; Eric M Reiman; Clifford R Jack; Nick C Fox; William J Jagust; Danielle J Harvey; Laurel A Beckett; Anthony Gamst; Paul S Aisen; Ron C Petersen; Michael W Weiner
Journal:  Alzheimers Dement       Date:  2011-09       Impact factor: 21.566

4.  Brain structure and function as mediators of the effects of amyloid on memory.

Authors:  Niklas Mattsson; Philip S Insel; Paul S Aisen; William Jagust; Scott Mackin; Michael Weiner
Journal:  Neurology       Date:  2015-02-13       Impact factor: 9.910

5.  Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study.

Authors:  Duygu Tosun; Norbert Schuff; Diana Truran-Sacrey; Leslie M Shaw; John Q Trojanowski; Paul Aisen; Ronald Peterson; Michael W Weiner
Journal:  Neurobiol Aging       Date:  2010-06-08       Impact factor: 4.673

Review 6.  CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Authors:  Craig Ritchie; Nadja Smailagic; Anna H Noel-Storr; Obioha Ukoumunne; Emma C Ladds; Steven Martin
Journal:  Cochrane Database Syst Rev       Date:  2017-03-22

7.  Relationship between CSF biomarkers of Alzheimer's disease and rates of regional cortical thinning in ADNI data.

Authors:  Duygu Tosun; Norbert Schuff; Leslie M Shaw; John Q Trojanowski; Michael W Weiner
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

8.  Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease.

Authors:  W J P Henneman; H Vrenken; J Barnes; I C Sluimer; N A Verwey; M A Blankenstein; M Klein; N C Fox; P Scheltens; F Barkhof; W M van der Flier
Journal:  Neurology       Date:  2009-09-22       Impact factor: 9.910

9.  Role of structural MRI in Alzheimer's disease.

Authors:  Prashanthi Vemuri; Clifford R Jack
Journal:  Alzheimers Res Ther       Date:  2010-08-31       Impact factor: 6.982

10.  White matter hyperintensities and amyloid are independently associated with entorhinal cortex volume among individuals with mild cognitive impairment.

Authors:  Vanessa A Guzman; Owen T Carmichael; Christopher Schwarz; Giuseppe Tosto; Molly E Zimmerman; Adam M Brickman
Journal:  Alzheimers Dement       Date:  2013-01-30       Impact factor: 21.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.